Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Raymond James Trust N.A.

Raymond James Trust N.A. grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 34.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 754 shares of the company’s stock after purchasing an additional 194 shares during the quarter. Raymond James Trust N.A.’s holdings in Medpace were worth $252,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Cetera Advisors LLC raised its stake in Medpace by 162.4% during the 1st quarter. Cetera Advisors LLC now owns 2,608 shares of the company’s stock worth $1,054,000 after acquiring an additional 1,614 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Medpace by 175.6% during the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock worth $4,966,000 after purchasing an additional 9,478 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Medpace in the 1st quarter valued at about $1,239,000. CWA Asset Management Group LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at about $1,306,000. Finally, Oppenheimer Asset Management Inc. grew its stake in Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after buying an additional 2,675 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.1 %

NASDAQ MEDP opened at $338.96 on Thursday. The business’s 50 day moving average is $338.93 and its two-hundred day moving average is $371.98. The stock has a market capitalization of $10.53 billion, a price-to-earnings ratio of 29.68, a PEG ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.22 earnings per share. Equities analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MEDP. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price target for the company from $420.00 to $350.00 in a research report on Friday, September 27th. TD Cowen lowered their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird upped their target price on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.